INTRODUCTION
In recent
years a significant reassessment of the nature and causes of cancer has
taken place. Cancer was formerly believed to be a localized disease, characterized
by a lesion, usually in the form of a growth, which appeared at some specific
part of the body. This localized lesion was thought to be the result of
a activity produced by an invading virus, carcinogenic agent, or some
form of trauma such as a blow.
Today, there
is a growing conviction among researchers and physicians that cancer is
a complex disease that is the end result of a disturbed metabolism (body
chemistry). It is a insidious disease that involves the entire body; the
nervous system, digestive track, pancreas, lungs, excretory organs, endocrine
system and the entire defense mechanism. The frequent reoccurrence of
a malignancy after treatment with the conventional methods of surgery,
radiation and/or chemotherapy, results because the basic underlying metabolic
cause of the cancer is rarely considered and consequently remains uncorrected.
MODE
OF ACTION
Amygdalin
(laetrile or B17 are the same) is a relatively simple compound found in
much of our food supply. It is most abundant in the seeds of non-citrus
fruits. Most commercially prepared amygdalin is extracted from the seeds
of the apricot.
Amygdalin
is composed of two molecules of glucose (a sugar), one molecule of hydrocyanic
acid (an anti-neoplastic compound), and one molecule of benzaldehyde (an
analgesic).
In metabolic
therapy, the amygdalin is broken down into its component parts as a result
of the action of the betaglucidase. This enzyme is found in abundance
in cancer cells, and is relatively deficient in normal cells.
Consequently,
the cyanide is released only where there is an active cancer lesion. This
liberation of cyanide under controlled and safe conditions insures that
an adequate dosage can be administered without the threat of toxic side
effects. This absence of cyanide toxicity is further insured by the action
of the thodanese, another enzyme. This enzyme is present in large quantities
in normal cells but is very small amounts in cancer cells.
Detoxification
of cyanide occurs, therefore, in normal mammalian tissue through the action
of this rhodanese which, in the presence of sulfer-bearing compounds,
converts free cyanide to thiocyanate, a perfectly nontoxic compound. The
thiocynate is excreted in the urine.
ADMINISTRATION
OF AMYGDALIN
Slow drip
infusion. The most efficacious mode of administration is through the slow-drip
infusion technique which was developed in Tijuana, Mexico. It became apparent
that the breakdown of amygdalin and its subsequent detoxification was
very rapid. If it were to be administered over a longer period of time,
this could be overcome. In addition, the amygdalin must pass through many
biological membranes in order to reach it site of action. This can be
accomplished by combining the amygdalin with Dimethylsulfoxide (DMSO-labratory
grade). Finally, as vitamin C is known to slow the growth of tumors, it
is added to allow the amygdalin and the rest of the metabolic therapy
more time to work.
The amygdalin
should be added just prior to injection to insure maximum potency. This
complete infusion is administered intravenously over a 2 to 3 hour period.
More rapid
administration can result in a localized burning sensation due to the
large amounts of vitamin C. This infusion is administered daily over the
first 21 days of metabolic therapy.
Intravenous
Injection. In some instance where the slow drip infusion is not practical,
intravenous administration of amygdalin can be used. This method provides
the same high concentration in the blood as the slow drip infusion. Three
vials (3 grams each) are administered daily in a slow intravenous push,
usually in the brachial vein just proximate to the elbow. Preferably this
administration should be between meals. The intravenous administration
should be daily for 21 days.
Oral Ingestion.
This is the most convenient and most frequently used method of amygdalin
administration. The patients leaving the clinic are placed on oral amygdalin.
Also, because of the difficulty for some patients in going to the physicians
daily, many doctors prefer this method.
For treatment:
The tablet side is 500 milligrams (mg). Two of these tablets should be
given 3 times a day. If patients have difficulty swallowing, the tablets
may be broken up and added to the soft food. The patient should take 1
tablet six times a day.
As a preventive:
The tablet size is 100mg. One or two tablets should be taken daily.
This data
is provided for informational purposes only by Cyto Pharma of Mexico.
This company has been in the market since 1971 and are well known worldwide.
They are the leader in the field of the amygdalin process and their research
staff is constantly working to upgrade their products.
Certificate
of Analysis of B17/Amygdalin/Latetrile tablets
as provided by Cyto Pharma of Mexico
